President Donald Trump wants to remake the Food and Drug Administration. And he happens to have a “fantastic person” in mind to do it, he said Tuesday — someone who will turn the agency into an industry-friendly shop that cranks out new cures on the double.

But does anyone really want a deregulated FDA? STAT canvassed biopharma insiders, physicians, Wall Street analysts, and FDA veterans. Their verdict: Trump’s plan sounds like a solution in search of a problem.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • If Trump can bring sweeping changes in the structure of FDA and a FDA Moderation Act to make medicines available to patients at affordable price, it will be welcome with open arms. Deregulation cannot happen – however, moderation can. Medicines require regulation but with well defined stages of regulation. Drug Development studies should be done with cell lines and not on human beings. Our science has advanced so much that new technologies can be introduced for drug development – cutting development cost and time. FDA should have experts from industry coopted for special task force teams for the Moderation Act.

  • très bonne chose pour les patients en train de mourir sans aucun espoir, pour ces gens là, un jour compte, une heure même un e minute
    Pour des fonctionnaires de la FDA, ils ont tout leur temps, pourquoi prendrait-il me plus petit risque
    Trump a de la compassion, formidable président

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy